| Age (median) | 45 yr | (19-59 yr) |
| Patient/donor | ||
| Sex | ||
| M/M | 11 | |
| F/F | 9 | |
| M/F | 9 | |
| F/M | 11 | |
| Disease | ||
| CML | 25 | |
| Cytogenetic relapse | 10 | |
| Stable phase | 9 | |
| Accelerated phase | 3 | |
| Blast crisis | 3 | |
| MM | 7 | |
| AML | 4 | |
| ALL | 1 | |
| NHL | 1 | |
| CLL | 1 | |
| MDS | 1 | |
| BMT/GVHD prophylaxis | ||
| CD6 T-cell depletion | 39 | |
| Cyclosporine/methotrexate | 1 | |
| Time from transplant to relapse (median) | 21 mo | (2-62 mo) |
| Time from relapse to DLI (median) | 13 mo | (1-75 mo) |
| Time from BMT to DLI (median) | 26 mo | (7-91 mo) |
| Interferon pre-DLI | 10 | |
| Follow-up (median) | 50 wk | (8-129 wk) |
| Age (median) | 45 yr | (19-59 yr) |
| Patient/donor | ||
| Sex | ||
| M/M | 11 | |
| F/F | 9 | |
| M/F | 9 | |
| F/M | 11 | |
| Disease | ||
| CML | 25 | |
| Cytogenetic relapse | 10 | |
| Stable phase | 9 | |
| Accelerated phase | 3 | |
| Blast crisis | 3 | |
| MM | 7 | |
| AML | 4 | |
| ALL | 1 | |
| NHL | 1 | |
| CLL | 1 | |
| MDS | 1 | |
| BMT/GVHD prophylaxis | ||
| CD6 T-cell depletion | 39 | |
| Cyclosporine/methotrexate | 1 | |
| Time from transplant to relapse (median) | 21 mo | (2-62 mo) |
| Time from relapse to DLI (median) | 13 mo | (1-75 mo) |
| Time from BMT to DLI (median) | 26 mo | (7-91 mo) |
| Interferon pre-DLI | 10 | |
| Follow-up (median) | 50 wk | (8-129 wk) |
Ranges are given in parentheses.